Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03995667 · ClinicalTrials.gov registry record · Phase 2
Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03995667 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 3 participants.
The verdict
NCT03995667, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II single-arm pilot study will evaluate the safety and preliminary efficacy of Optune-Tumor Treating Fields (TTFields) therapy as a prophylactic approach to reducing small cell lung cancer (SCLC) that has spread to the brain (brain metastases). Optune is a portable battery powered device that produces alternating electrical fields, termed tumor treatment fields ("TTFields") within the human body. These TTFields are applied to the patient by electrically insulated surface transducer arrays, which function to disrupt the rapid cell division of cancer cells.
Interventions
- OTHER Questionnaire Administration
- DEVICE Tumor Treating Fields Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2022-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03995667
The ClinicalTrials.gov registry entry for NCT03995667 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT03995667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03995667 about?
NCT03995667 is a clinical study titled "Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer". This phase II single-arm pilot study will evaluate the safety and preliminary efficacy of Optune-Tumor Treating Fields (TTFields) therapy as a prophylactic approach to reducing small cell lung cancer (SCLC) that has spread to the brain (brain metastases). Optune is a portable battery powered device ...
What is the current status of trial NCT03995667?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-06-11. Estimated completion is 2022-08-04.
What interventions are being tested in trial NCT03995667?
The interventions under investigation include: Questionnaire Administration (OTHER), Tumor Treating Fields Therapy (DEVICE).
Who is sponsoring clinical trial NCT03995667?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.